Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.55 |
| ▸ | RXRA | P19793 | 15/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20335480 | 0.89 | ATAD2 (0.43) | ATAD2RXRAHDAC1HDAC6CYP19A1 | |
| SCHEMBL2061101 | 0.86 | ATAD2 (0.59) | ATAD2RXRAHDAC1HDAC6CYP19A1 | |
| SCHEMBL18421516 | 0.83 | RXRA (0.44) | ATAD2RXRAHDAC1HDAC6 | |
| SCHEMBL27376724 | 0.82 | HDAC1 (0.52) | HDAC1HDAC6PGR | |
| SCHEMBL5189901 | 0.82 | RXRA (0.45) | ATAD2RXRAHDAC1HDAC6 | |
| SCHEMBL18421544 | 0.81 | BRD4 (0.42) | ATAD2RXRAHDAC1HDAC6 | |
| SCHEMBL9593284 | 0.80 | CYP19A1 (0.46) | ATAD2RXRAHDAC1HDAC6CYP19A1 | |
| SCHEMBL8310714 | 0.80 | CYP1A2 (0.43) | RXRAHDAC1HDAC6 | |
| SCHEMBL1368159 | 0.77 | ATAD2 (0.48) | ATAD2CYP19A1PGR | |
| SCHEMBL7709931 | 0.77 | RARA (0.56) | ATAD2RXRAHDAC1HDAC6CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0933350-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933351-A1 | Tricyclic retinoids, methods for their production and use | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5770382-A | RETINOIC ACID AND RETINOID X RECEPTOR AGONISTS; TREATINGSKIN, EYE, BRAIN, AND CARDIOVASCULAR DISORDERS; CANCER | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770378-A | A VITAMINE A METABOLITE, POTENT DRUGS TREATING SKIN DISEASES, CANCER, EYE DISEASES, CARDIOVASCULAR DISORDERS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5770383-A | ACTIVATE RETINOID RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| WO-1996020914-A1 | TRICYCLIC RETINOIDS, METHODS FOR THEIR PRODUCTION AND USE | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1996-07-11 | — | — | WO | disclosed |